title: Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
abstract: BACKGROUND
  Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment.
  
  
  METHODS
  We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, a SGLT-2 inhibitor, was determined to be the cause of the DKA. The patient ultimately recovered after 5 days in the intensive care unit. She was changed to long- and short-acting insulins and instructed to avoid canagliflozin.
  
  
  CONCLUSIONS
  Although SGLT-2 inhibitors are effective at lowering a patient's hemoglobin A1C, physicians must be aware of the rare but dangerous potential adverse effect of inducing DKA. This article reports an illustrative case and presents a review of the literature.
authors.affiliation: Texas Tech University Health Sciences Center, Amarillo, TX, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Turner
authors.affiliation: Texas Tech University Health Sciences Center, Amarillo, TX, USA.
authors.forename: Tahmina
authors.initials: T
authors.lastname: Begum
authors.affiliation: Texas Tech University Health Sciences Center, Amarillo, TX, USA.
authors.forename: Roger D
authors.initials: RD
authors.lastname: Smalligan
keywords: SGLT-2 inhibitors; canagliflozin; diabetic ketoacidosis